Comment on Is Geron Corporation's Stock Set to Sail or Sink?

Is Geron Corporation's Stock Set to Sail or Sink?

Geron Corp. (NASDAQ: GERN), a small-cap cancer company, released its fourth-quarter and full-year earnings after the bell last Friday. While earnings for developmental-stage biotechs like Geron are generally meaningless, the company did update investors on the progress of the collaboration with Johnson & Johnson's (NYSE: JNJ) biotech subsidiary Janssen. The two companies are presently developing the first-in-class telomerase inhibitor, imetelstat, for a basket of blood-based cancers. Oddly enough, though, Geron decided to bury the most important of these clinical updates deep in the press release, and it also left out another major regulatory update altogether. Image Source: Getty Images.Continue reading

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News